Psoriasis patients exhibit impairment of the high potency CCR5+ T regulatory cell subset

Clinical Immunology

Volumn 149, Issue 1, 2013, Pages 111-118

  Soler, David C ^b,c   Sugiyama, Hideaki ^a,b   Young, Andrew B ^b   Massari, Jessica V ^b   McCormick, Thomas S ^b,c   Cooper, Kevin D ^b,c  

^a Seirei Yokohama General Hospital   (Japan)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Immunosuppression; Psoriasis; Regulatory T cells

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MACROPHAGE INFLAMMATORY PROTEIN 1; RANTES;

ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

IMMUNOSUPPRESSION; PSORIASIS; REGULATORY T CELLS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; CHEMOKINE CCL5; CHEMOTAXIS; HUMANS; PSORIASIS; RECEPTORS, CCR5; T-LYMPHOCYTES, REGULATORY;

EID: 84882772344     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.06.007     Document Type: Article

References (34)

1. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
2. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
3. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., Gottlieb P.A., Kapranov P., Gingeras T.R., Fazekas de St Groth B., Clayberger C., Soper D.M., Ziegler S.F., Bluestone J.A. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 2006, 203:1701-1711.
4. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., Kelly T.E., Saulsbury F.T., Chance P.F., Ochs H.D. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 2001, 27:20-21.
5. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., Wilkinson J.E., Galas D., Ziegler S.F., Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 2001, 27:68-73.
6. Campanelli A.P., Roselino A.M., Cavassani K.A., Pereira M.S., Mortara R.A., Brodskyn C.I., Goncalves H.S., Belkaid Y., Barral-Netto M., Barral A., Silva J.S. CD4+CD25+ T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J. Infect. Dis. 2006, 193:1313-1322.
7. Kleinewietfeld M., Puentes F., Borsellino G., Battistini L., Rotzschke O., Falk K. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 2005, 105:2877-2886.
8. Colantonio L., Iellem A., Sinigaglia F., D'Ambrosio D. Skin-homing CLA+ T cells and regulatory CD25+ T cells represent major subsets of human peripheral blood memory T cells migrating in response to CCL1/I-309. Eur. J. Immunol. 2002, 32:3506-3514.
9. Dobaczewski M., Xia Y., Bujak M., Gonzalez-Quesada C., Frangogiannis N.G. CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. Am. J. Pathol. 2010, 176:2177-2187.
10. Zamilpa R., Kanakia R., Cigarroa J.t., Dai Q., Escobar G.P., Martinez H., Jimenez F., Ahuja S.S., Lindsey M.L. CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H1418-H1426.
11. Medeiros G.A., Silverio J.C., Marino A.P., Roffe E., Vieira V., Kroll-Palhares K., Carvalho C.E., Silva A.A., Teixeira M.M., Lannes-Vieira J. Treatment of chronically Trypanosoma cruzi-infected mice with a CCR1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage. Microbes Infect. 2009, 11:264-273.
12. Machado F.S., Koyama N.S., Carregaro V., Ferreira B.R., Milanezi C.M., Teixeira M.M., Rossi M.A., Silva J.S. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J. Infect. Dis. 2005, 191:627-636.
13. Luangsay S., Kasper L.H., Rachinel N., Minns L.A., Mennechet F.J., Vandewalle A., Buzoni-Gatel D. CCR5 mediates specific migration of Toxoplasma gondii-primed CD8 lymphocytes to inflammatory intestinal epithelial cells. Gastroenterology 2003, 125:491-500.
14. Bettini M., Vignali D.A. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr. Opin. Immunol. 2009, 21:612-618.
15. Paust S., Cantor H. Regulatory T cells and autoimmune disease. Immunol. Rev. 2005, 204:195-207.
16. Bettelli E., Oukka M., Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 2007, 8:345-350.
17. Weaver C.T., Murphy K.M. The central role of the Th17 lineage in regulating the inflammatory/autoimmune axis. Semin. Immunol. 2007, 19:351-352.
18. Sugiyama H., Gyulai R., Toichi E., Garaczi E., Shimada S., Stevens S.R., McCormick T.S., Cooper K.D. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 2005, 174:164-173.
19. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
20. Goodman W.A., Levine A.D., Massari J.V., Sugiyama H., McCormick T.S., Cooper K.D. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J. Immunol. 2009, 183:3170-3176.
21. Goodman W.A., Young A.B., McCormick T.S., Cooper K.D., Levine A.D. Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J. Immunol. 2011, 186:3336-3345.
22. Chang L.Y., Lin Y.C., Kang C.W., Hsu C.Y., Chu Y.Y., Huang C.T., Day Y.J., Chen T.C., Yeh C.T., Lin C.Y. The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells. J. Immunol. 2012, 189:567-574.
23. Szabo S.K., Hammerberg C., Yoshida Y., Bata-Csorgo Z., Cooper K.D. Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J. Invest. Dermatol. 1998, 111:1072-1078.
24. Nestle F.O. Psoriasis. Curr. Dir. Autoimmun. 2008, 10:65-75.
25. Ajuebor M.N., Carey J.A., Swain M.G. CCR5 in T cell-mediated liver diseases: what's going on?. J. Immunol. 2006, 177:2039-2045.
26. Slimani H., Charnaux N., Mbemba E., Saffar L., Vassy R., Vita C., Gattegno L. Interaction of RANTES with syndecan-1 and syndecan-4 expressed by human primary macrophages. Biochim. Biophys. Acta 2003, 1617:80-88.
27. Yurchenko E., Tritt M., Hay V., Shevach E.M., Belkaid Y., Piccirillo C.A. CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J. Exp. Med. 2006, 203:2451-2460.
28. Bogunia-Kubik K., Duda D., Suchnicki K., Lange A. CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica 2006, 91:1628-1634.
29. Wysocki C.A., Jiang Q., Panoskaltsis-Mortari A., Taylor P.A., McKinnon K.P., Su L., Blazar B.R., Serody J.S. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005, 106:3300-3307.
30. de Groot M., Teunissen M.B., Ortonne J.P., Lambert J.R., Naeyaert J.M., Picavet D.I., Arreaza M.G., Simon J.S., Kraan M., Bos J.D., de Rie M.A. Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch. Dermatol. Res. 2007, 299:305-313.
31. Rateb A.A., Fawzi M.M., Abdel Hay R.M., Mohammed F.N., Amr K.S. Reduction of RANTES expression in lesional psoriatic skin after narrow band ultraviolet therapy: a possible marker of therapeutic efficacy. Eur. J. Dermatol. 2012, 22:481-487.
32. Chen L., Wu J., Pier E., Zhao Y., Shen Z. mTORC2-PKBalpha/Akt1 Serine 473 phosphorylation axis is essential for regulation of FOXP3 Stability by chemokine CCL3 in psoriasis. J. Invest. Dermatol. 2012, 133:418-428.
33. Pedrosa E., Carretero-Iglesia L., Boada A., Colobran R., Faner R., Pujol-Autonell I., Palou E., Esteve A., Pujol-Borrell R., Ferrandiz C., Juan M., Carrascosa J.M. CCL4L polymorphisms and CCL4/CCL4L serum levels are associated with psoriasis severity. J. Invest. Dermatol. 2011, 131:1830-1837.
34. Bovenschen H.J., van de Kerkhof P.C., van Erp P.E., Woestenenk R., Joosten I., Koenen H.J. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J. Invest. Dermatol. 2012, 131:1853-1860.